Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00

Key Points

• Needham raised Axsome Therapeutics’ price target to $268 from $267 and maintained a “buy” rating, implying roughly 21.3% upside from the reported share price.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $266.20; targets from other firms range from $258 to $306.
• Axsome reported a quarterly loss of $0.99 per share, missing the $0.89 consensus estimate, while revenue of $218.38 million also fell slightly short of expectations. The company remains unprofitable, and insiders sold approximately $46.7 million of stock over the past quarter.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price objective boosted by research analysts at Needham & Company LLC from $267.00 to $268.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's price objective would suggest a potential upside of 21.33% from the company's current price.

Several other research firms also recently weighed in on AXSM. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday, May 4th. Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a research report on Monday, June 15th. Mizuho dropped their price target on Axsome Therapeutics from $310.00 to $306.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Piper Sandler reaffirmed an "overweight" rating and issued a $258.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $272.00 price objective on shares of Axsome Therapeutics in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $266.20.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $220.89 on Tuesday. The company has a market cap of $11.37 billion, a price-to-earnings ratio of -59.22 and a beta of 0.65. The business's fifty day simple moving average is $236.76 and its two-hundred day simple moving average is $204.41. Axsome Therapeutics has a 12 month low of $102.67 and a 12 month high of $260.19. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The business had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%. Research analysts anticipate that Axsome Therapeutics will post -2.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 4,660 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the transaction, the chief executive officer owned 7,229 shares of the company's stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark Coleman sold 643 shares of the business's stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the sale, the director owned 30,389 shares of the company's stock, valued at approximately $7,566,861. This represents a 2.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 200,766 shares of company stock valued at $46,685,646 over the last quarter. 20.60% of the stock is owned by company insiders.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vise Technologies Inc. bought a new position in shares of Axsome Therapeutics in the 2nd quarter worth $605,000. Lisanti Capital Growth LLC acquired a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $5,097,000. Csenge Advisory Group acquired a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $506,000. Tocqueville Asset Management L.P. purchased a new position in shares of Axsome Therapeutics in the second quarter valued at approximately $563,000. Finally, NewEdge Wealth LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter worth approximately $851,000. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Management indicated a potentially significant development cadence, targeting approximately one new drug application (NDA) annually through 2030. AXS-12, its narcolepsy candidate, is scheduled for a May 1, 2027 PDUFA date, providing a defined regulatory catalyst. Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA
• Positive Sentiment: Axsome’s commercial sales growth helped offset the quarterly earnings shortfall, supporting investor confidence in the company’s marketed-product base and revenue trajectory. Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss
• Positive Sentiment: The company’s second-quarter business update and presentation emphasized ongoing pipeline progress and corporate development, reinforcing the longer-term growth case for AXSM. Axsome Therapeutics Announces Q2 2026 Financial Results and Updates Corporate Presentation
• Neutral Sentiment: Second-quarter revenue was $218.38 million, close to—but below—the $221.11 million analyst consensus. Coverage is focused on whether key operating metrics and sales trends can sustain Axsome’s mid-cap growth profile. Axsome Q2 Earnings: What Key Metrics Have to Say
• Negative Sentiment: Axsome reported a second-quarter loss of $0.99 per share, wider than the $0.89 consensus estimate. The company remains unprofitable, with a negative net margin, so execution and progress toward sustainable earnings remain important risks. Axsome Therapeutics Second-Quarter Earnings Results

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source